[Preclinical evaluation of a veno-venous bypass device for liver transplantation based on the principle of magnetic levitation drive].

Objective: To explore the performance of a self-made venous-venous bypass (VVB) device for liver transplantation based on the principle of magnetic levitation drive. Methods: Experimental study was conducted from August 2020 to January 2022. Eight Bama minipigs underwent VVB of hepatic portal vein-femoral vein-internal jugular vein after occlusion of hepatic portal vein and inferior vena cava. The animals were divided into two groups according to the VVB devices used during VVB. A self-made VVB device was used in group A(n=5),and an imported VVB device was used in group B(n=3). The hemodynamic changes of the two groups of animals were compared at 6 time points including before vascular occlusion, during vascular occlusion, 30 minutes, 60 minutes, 90 minutes after the start of VVB, and 30 minutes after vascular opening. In addition,the changes of blood compatibility indexes,intestinal injury indexes,kidney injury indexes and internal environment indexes of the two groups of animals at each time point were compared. The independent samples t test was used for the quantitative data between the two groups with non-repeated measures,and the repeated measures analysis of variance was used for the quantitative data between the two groups with repeated measures. Results: During the VVB of the two devices,the venous drainage was sufficient,and the main manifestations were that the color of the intestine of the Bama miniature pig was ruddy, the peristalsis was normal, and the urine output was normal. There were no significant differences in hemodynamics,blood injure indexes,intestinal injury indexes,kidney injury indexes,neutropil gelatinase-associated lipocalin,and internal environment indexes(all P>0.05).The indexes at 30 minutes after vascular opening in the group A and the group B were as follows:mean arterial pressure were (71.0±7.7)mmHg(1 mmHg=0.133 kPa) and (74.0±8.7)mmHg,central venous pressure were (7.0±1.4)cmH2O(1 cmH2O=0.098 kPa) and (7.7±0.6)cmH2O,heart rate were (131±10) beats/minutes and (132±8)beats/minutes; red blood cell count were (6.43±0.89)×1012/L and (6.32±0.58)×1012/L,hemoglobin were (108.4±5.9)g/L and (110.0±3.5)g/L,free hemoglobin were (78.28±3.96)mg/L and (78.08±4.54)mg/L; intestinal fatty acid binding protein were (2.27±0.49)µg/L and (2.40±0.78)µg/L;creatinine were (68.30±9.77)µmol/L and (79.90±26.91)µmol/L,blood urea nitrogen were (3.94±1.39)mmol/L and (3.45±0.65)mmol/L;neutropil gelatinase-associated lipocalin were (4.02±0.53) µg/L and (3.86±0.23)µg/L;pH value were 7.27±0.04 and 7.23±0.03,lactic acid were (6.18±2.62)mmol/L and (4.30±0.50)mmol/L,concentrations of Na+ were (136.3±3.0)mmol/L and (137.6±1.6) mmol/L,concentrations of K+ were (3.89±0.42) mmol/L and (3.98±0.17)mmol/L,concentrations of Ca2+ were (1.40±0.03)mmol/L and(1.40±0.04)mmol/L;all indexes in the two group had no differences(all P>0.05). Conclusion: The self-made venous bypass device can be safely and effectively applied to VVB of Bama minipigs,and achieves the same performance as the imported venous bypass device.

1,25-Dihydroxyvitamin D3 regulates T lymphocyte proliferation through activation of P53 and inhibition of ERK1/2 signaling pathway in children with Kawasaki disease.

OBJECTIVE: To study the effect of 1,25(OH)2D3 on T lymphocytes in Kawasaki disease and to further investigate its molecular mechanism. PATIENTS AND METHODS: A total of 30 child patients was diagnosed as Kawasaki disease, 60 child patients were diagnosed as infectious fever, and 60 normal children, were selected. 4 mL peripheral blood was collected before treatment. Peripheral blood mononuclear cells were isolated and separated using the Facollin method and cultured. Flow cytometry was used to identify T cells. The cell sections were prepared for immunohistochemical staining. After T cells in each group were treated with 1,25(OH)2D3, the proteins were extracted for Western blotting. RESULTS: Peripheral blood T cells were successfully isolated and cultured, and the maximal atoxic concentration of 1,25(OH)2D3 on T cells was 10-3 µmol/L. In T cells of child patients with Kawasaki disease, signal transducer and activator of transcription 3 (STAT3) were continuously activated, P53 apoptosis genes were inactivated, and nuclear factor κB (NF-κB) P65 pathway and extracellular signal-regulated kinase (ERK) pathway were activated. After the intervention with 1,25(OH)2D3 in vitro, STAT3 and NF-κB P65 had no significant changes, the activation of ERK1/2 signaling pathway was inhibited and the P53 protein was activated. CONCLUSIONS: Apoptotic T cells in peripheral blood in KD cannot initiate the normal apoptosis program, so they continue to proliferate and differentiate, eventually leading to the increase and abnormal activation of T cells and the immune imbalance in the body. 1,25(OH)2D3 can inhibit the excess hyperplasia of T cells through adjusting partial signal transduction pathway.

[A comparative study between gallium alloy and amalgan for the creep and clinical handing]

OBJECTIVE: This study showed that the creep value of gallium alloy is higher than that of amalgam,but it was within the limits permitted by ISO.It was suggested that the poor handing characteristics of gallium alloy may make it difficult to use in clinic.So,if gallium alloy could use in the clinic or not,according to it's clinical handling characteristic.

[Progress in the study of inhibin subunit gene expression and regulation in mammalian ovary].

Inhibin is a glycoprotein hormone composed of an alpha-subunit and a beta-subunit. It suppresses pituitary FSH secretion. Activin is a dimer of beta-subunits of inhibin, which stimulates pituitary FSH secretion. This review is a survey of recent research progress in gene expression and regulation of inhibin/activin, particularly pointing out some questions in studying gene expression of inhibin.

[The study of inhibin/activin formation in human corpus luteum].

The expression of alpha, beta A, and beta B subunit mRNAs is observed in human corpus luteum (CL) of early (3rd day), mid (8th day) and late (15th day) luteal phase during human menstrual cycle. alpha-mRNAs peaked in early CL; beta A-mRNAs appeared only in early CL; beta B-mRNAs was found in early luteal phase and peaked in late CL. The results suggest that (1) inhibin B (alpha.beta B dimer) rather than inhibin A (alpha.beta A dimer) might be the major form of inhibin secreted by human CL; (2) the late CL may produce activin B (beta B.beta B dimer).